Canopy Growth Corp's June 15, 2026 8-K filing reveals a significant restatement of prior financial statements caused by material misstatements and a disclosed material weakness in internal controls over financial reporting. The remediation process is underway but has incurred notable costs, weighed down by ongoing litigation risk and impaired investor confidence. Operationally, Canopy continues to pursue growth through acquisitions, expanded cultivation capacity, and product diversification within medical and recreational cannabis segments, although reimbursement rate pressures and regulatory compliance remain key constraints. The latest quarter reflects sustained losses against a solid liquidity buffer, positioning the company to support remediation efforts while navigating competitive sector dynamics.